Patricio Perez-Villarroel
Overview
Explore the profile of Patricio Perez-Villarroel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
447
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takahashi H, Perez-Villarroel P, Falahat R, Mule J
J Immunother Cancer
. 2025 Mar;
13(3).
PMID: 40081947
Background: Strategies to improve the therapeutic efficacy of cancer immunotherapy with immune checkpoint inhibitors include targeting additional immunosuppressive compartments in the tumor microenvironment (TME). Inhibitory macrophages (Mφ) can be one...
2.
Cheng F, Lienlaf M, Wang H, Perez-Villarroel P, Lee C, Woan K, et al.
J Immunol
. 2024 Sep;
213(7):1044.
PMID: 39284121
No abstract available.
3.
Falahat R, Berglund A, Perez-Villarroel P, Putney R, Hamaidi I, Kim S, et al.
Nat Commun
. 2023 Mar;
14(1):1573.
PMID: 36949064
While STING-activating agents have shown limited efficacy in early-phase clinical trials, multiple lines of evidence suggest the importance of tumor cell-intrinsic STING function in mediating antitumor immune responses. Although STING...
4.
Aoyama S, Nakagawa R, Nemoto S, Perez-Villarroel P, Mule J, Mailloux A
J Immunother Cancer
. 2021 Jun;
9(6).
PMID: 34135102
Background: The temporal response to checkpoint blockade (CB) is incompletely understood. Here, we profiled the tumor infiltrating lymphocyte (TIL) landscape in response to combination checkpoint blockade at two distinct timepoints...
5.
Falahat R, Berglund A, Putney R, Perez-Villarroel P, Aoyama S, Pilon-Thomas S, et al.
Proc Natl Acad Sci U S A
. 2021 Apr;
118(15).
PMID: 33827917
Lack or loss of tumor antigenicity represents one of the key mechanisms of immune escape and resistance to T cell-based immunotherapies. Evidence suggests that activation of stimulator of interferon genes...
6.
Falahat R, Perez-Villarroel P, Mailloux A, Zhu G, Pilon-Thomas S, Barber G, et al.
Cancer Immunol Res
. 2019 Aug;
7(11):1837-1848.
PMID: 31462408
STING (stimulator of IFN genes) signaling is an innate immune pathway for induction of a spontaneous antitumor T-cell response against certain immunogenic tumors. Although antigen-presenting cells are known to be...
7.
Zhu G, Nemoto S, Mailloux A, Perez-Villarroel P, Nakagawa R, Falahat R, et al.
Front Immunol
. 2018 Aug;
9:1609.
PMID: 30061886
Tertiary lymphoid structures (TLSs) associate with better prognosis in certain cancer types, but their underlying formation and immunological benefit remain to be determined. We established a mouse model of TLSs...
8.
Sahakian E, Chen J, Powers J, Chen X, Maharaj K, Deng S, et al.
J Leukoc Biol
. 2017 May;
102(2):475-486.
PMID: 28550123
Epigenetic changes in chromatin structure have been recently associated with the deregulated expression of critical genes in normal and malignant processes. HDAC11, the newest member of the HDAC family of...
9.
Chen J, Sahakian E, Powers J, Lienlaf M, Perez-Villarroel P, Knox T, et al.
Methods Mol Biol
. 2016 Aug;
1436:E1.
PMID: 27535557
No abstract available.
10.
Chen J, Sahakian E, Powers J, Lienlaf M, Perez-Villarroel P, Knox T, et al.
Methods Mol Biol
. 2016 Jun;
1436:147-65.
PMID: 27246214
The physiological role of histone deacetylase 11 (HDAC11), the newest member of the HDAC family, remained largely unknown until the discovery of its regulatory function in immune cells. Among them,...